Samsung Biologics to buy PolyPeptide for $1.8bn in cash

Samsung Biologics (207940.KS) said Monday it would buy PolyPeptide Group (PPGN.SW) for CHF 1.46 billion ($1.8 billion) in cash, using a cross-border tender offer to add peptide manufacturing capacity as Samsung shares fell 1.5 per cent and PolyPeptide dropped 8.7 per cent.

Under the offer, the Swiss drug-manufacturing supplier is valued at CHF 44.31 a share, or a 40 per cent premium to PolyPeptide’s undisturbed price, Samsung said. Management wants to move further beyond antibodies and antibody-drug conjugates into peptides, including GLP-1 therapies, where specialist manufacturing has become a constraint for drugmakers.

Strategically, Samsung is betting that an established peptide platform can save years of organic expansion. Customers in outsourced drug manufacturing care about regulatory familiarity and supply reliability as much as headline capacity.

PolyPeptide’s board supports the proposal, and the target’s largest holder, with 55.65 per cent of the shares, has agreed to tender. Because Samsung needs 66⅔ per cent acceptance, the anchor stake does not finish the deal. It does reduce the room for a prolonged public fight.

Conditions remain. Samsung is taking on Swiss tender rules, a shareholder vote in practice through acceptances, and the ordinary work of binding a European peptide manufacturer into a Korean contract-development and manufacturing group. Early support lowers the deal risk; it does not erase it.

By paying cash, Samsung gives the offer another clean edge. PolyPeptide investors are not being asked to take stock in the enlarged company or wait for a slower plant-by-plant build-out. The bid is a fixed price for capacity, employees and customer relationships at a moment when peptide know-how is drawing more attention across the drug supply chain.

In its statement announcing the bid, Samsung quoted chief executive John Rim describing the acquisition as an extension of existing strategy, not a one-off expansion.

“This acquisition reinforces our long-term growth strategy by broadening our service portfolio into peptides, including GLP-1 therapies.”

John Rim, Samsung Biologics

What Samsung is buying

With PolyPeptide, Samsung gets a manufacturing map it cannot recreate quickly. Samsung said the target operates six production facilities in five countries, widening the South Korean group’s reach across Europe, the US and India.

That footprint is part of the price. Contract manufacturers compete partly on proximity to customers, regulators and supply chains, not just on factory volume. A buyer with plants in several markets can pitch for work that might be slower to win from one main base in Korea.

Peptide exposure is the other draw. GLP-1 obesity and diabetes treatments have put peptide capacity under closer scrutiny, but Samsung’s rationale is broader than one product cycle. Buying PolyPeptide gives it a working platform, technical employees and relationships with drugmakers on the day the deal closes.

Geography also shifts Samsung’s mix. The target’s network brings production in Europe, the US and India into a company whose core scale has been built in South Korea. That is useful for customers that want supply chains near clinical programmes or commercial launches.

Equity investors were not convinced. Samsung’s shares were lower on the session even after the company pointed to a larger global network, while PolyPeptide’s stock did not trade as if completion were risk-free. Integration, funding discipline and the timing of returns are the first questions for investors.

In separate remarks to Yonhap News Agency, Rim said the deal would accelerate Samsung’s business portfolio, production capacity and global foothold. If enough shareholders tender, Samsung will have bought a specialised manufacturing niche rather than a consumer-facing brand. For deal readers, the significance is in the financing and scale: a 40 per cent premium for faster peptide capacity, backed by a target footprint that makes the strategic fit easier to defend than the first-day share move.